Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267085 · ClinicalTrials.gov registry record · Phase 2
Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease
A Phase 2 study of Chronic Myeloid Leukemia and Minimal Residual Disease, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT00267085: Completed Phase 2 study of Chronic Myeloid Leukemia and Minimal Residual Disease, sponsored by M.D. Anderson Cancer Center.
NCT00267085 is a Phase 2 study of Chronic Myeloid Leukemia and Minimal Residual Disease that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 11 participants, below the 210-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00267085, a Phase 2 study of Chronic Myeloid Leukemia and Minimal Residual Disease, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if giving 1 of 2 CML (Chronic Myeloid Leukemia) vaccines (CML-VAX B2 or CML-VAX B3) together with imatinib mesylate can decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease.
Primary Outcome
Molecular response defined as reduction by one log of the circulating peripheral blood for reverse transcription polymerase chain reaction (RT-PCR) transcripts of BCR-ABL (tumor-specific oncogenic fusion protein) after two consecutive measurements. RT-PCR performed at 3 month intervals. Response categorized as either 'No Decrease' or 'Decrease' if one log reduction in BCR-ABL detected.
Conditions Studied
Interventions
- BIOLOGICAL Synthetic Tumor-Specific Breakpoint Peptide Vaccine
Study Locations (1)
Texas
- UT MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2005-12 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
What the finished NCT00267085 record still lists
NCT00267085 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 210-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Synthetic Tumor-Specific Breakpoint Peptide Vaccine is the first listed.
NCT00267085 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00267085 about?
NCT00267085 is a clinical study titled "Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease". The goal of this clinical research study is to learn if giving 1 of 2 CML (Chronic Myeloid Leukemia) vaccines (CML-VAX B2 or CML-VAX B3) together with imatinib mesylate can decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesyl...
What is the current status of trial NCT00267085?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2005-12. Estimated completion is 2008-07.
What conditions does trial NCT00267085 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia, Minimal Residual Disease.
What interventions are being tested in trial NCT00267085?
The interventions under investigation include: Synthetic Tumor-Specific Breakpoint Peptide Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00267085?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00267085 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00267085's enrollment target sits among peer trials
11 33rd of 35 higher than 3 of 35 other Chronic Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
RECRUITING · Phase 2
-
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
RECRUITING · Phase 2
-
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
RECRUITING · Phase 2
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
ACTIVE NOT RECRUITING · Phase 2
-
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia